These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31486700)

  • 1. Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.
    Ruszkowski P; Masajtis-Zagajewska A; Nowicki M
    J Renin Angiotensin Aldosterone Syst; 2019; 20(3):1470320319868890. PubMed ID: 31486700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of statin therapy added to ACE-inhibitors on blood pressure control and endothelial functions in normolipidemic hypertensive patients.
    Danaoğlu Z; Kültürsay H; Kayikçioğlu M; Can L; Payzin S
    Anadolu Kardiyol Derg; 2003 Dec; 3(4):331-7. PubMed ID: 14675884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels.
    Schneider MP; Schmidt BM; John S; Schmieder RE
    J Hypertens; 2011 Sep; 29(9):1757-64. PubMed ID: 21799442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Effects of ACE (Angiotensin-Converting Enzyme) Inhibitors and Statins in Adolescents With Type 1 Diabetes.
    Chiesa ST; Marcovecchio ML; Benitez-Aguirre P; Cameron FJ; Craig ME; Couper JJ; Davis EA; Dalton RN; Daneman D; Donaghue KC; Jones TW; Mahmud FH; Marshall SM; Neil HAW; Dunger DB; Deanfield JE;
    Hypertension; 2020 Dec; 76(6):1734-1743. PubMed ID: 33100044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
    Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
    Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
    Baker JV; Huppler Hullsiek K; Prosser R; Duprez D; Grimm R; Tracy RP; Rhame F; Henry K; Neaton JD
    PLoS One; 2012; 7(10):e46894. PubMed ID: 23082133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient.
    Kosch M; Barenbrock M; Suwelack B; Schaefer RM; Rahn KH; Hausberg M
    Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
    Wassmann S; Laufs U; Bäumer AT; Müller K; Ahlbory K; Linz W; Itter G; Rösen R; Böhm M; Nickenig G
    Hypertension; 2001 Jun; 37(6):1450-7. PubMed ID: 11408394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
    Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
    Deska P; Nowicki M
    J Physiol Pharmacol; 2017 Feb; 68(1):133-138. PubMed ID: 28456777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.
    Balletshofer BM; Goebbel S; Rittig K; Enderle M; Schmölzer I; Wascher TC; Ferenc Pap A; Westermeier T; Petzinna D; Matthaei S; Häring HU
    Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):324-30. PubMed ID: 15977099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.
    Leu HB; Chen JW; Wu TC; Ding YA; Lin SJ; Charng MJ
    Clin Cardiol; 2005 Sep; 28(9):423-8. PubMed ID: 16250265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
    Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
    Higashi Y; Sasaki S; Nakagawa K; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2001 Mar; 37(3):863-70. PubMed ID: 11693763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
    Koh KK; Quon MJ; Han SH; Ahn JY; Jin DK; Kim HS; Kim DS; Shin EK
    Hypertension; 2005 Jun; 45(6):1088-93. PubMed ID: 15883229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.
    Esper RJ; Machado R; Vilariño J; Cacharrón JL; Ingino CA; García Guiñazú CA; Bereziuk E; Bolaño AL; Suarez DH
    Am Heart J; 2000 Oct; 140(4):684-9. PubMed ID: 11011346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension.
    McGowan CL; Murai H; Millar PJ; Notarius CF; Morris BL; Floras JS
    Heart; 2013 Feb; 99(4):240-6. PubMed ID: 23257173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme.
    Hirota T; Ohki K; Kawagishi R; Kajimoto Y; Mizuno S; Nakamura Y; Kitakaze M
    Hypertens Res; 2007 Jun; 30(6):489-96. PubMed ID: 17664851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect and mechanism of HMG-CoA reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
    Yuan W; Fan H; Yang H; Tang L; Liu Z; Ouyang F; Luo W; Yan Y
    Diagn Pathol; 2023 Sep; 18(1):108. PubMed ID: 37759223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.